← Every company
Vertex Pharmaceuticals Inc Patents
What Vertex Pharmaceuticals Inc has filed at the patent office — applications as well as grants, because a filing is on the record eighteen months before anyone has to say what it was for.
VRTX on carbonthat →Filings on file
57
Granted
0
Still pending
57
Filed under
2 names
57 filings
Newest filing first. A pending application has no patent number yet, and most never get one.
| Invention | Patent |
|---|---|
| METHODS OF ENHANCING STEM CELL DIFFERENTIATION INTO BETA CELLSA61K 35/39, C07K 14/72, C12N 5/0676, A61P 3/08, C12N 9/1007, C12N 9/1029, C12N2501/065, C12N2501/11, C12N2501/15, C12N2501/155, C12N2501/16, C12N2501/999, C12N2506/02Filed as Vertex Pharmaceuticals Incorporated2026-04-21Felicia Pagliuca | pending |
| METHODS OF ENHANCING STEM CELL DIFFERENTIATION INTO BETA CELLSA61K 35/39, C07K 14/72, C12N 5/0676, A61P 3/08, C12N 9/1007, C12N 9/1029, C12N2501/065, C12N2501/11, C12N2501/15, C12N2501/155, C12N2501/16, C12N2501/999, C12N2506/02Filed as Vertex Pharmaceuticals Incorporated2026-04-21Felicia Pagliuca | pending |
| METHODS OF TREATMENT OF MYOTONIC DYSTROPHY TYPE 1Filed as VERTEX PHARMACEUTICALS INCORPORATED2026-03-25PEI LI | pending |
| SINTERED MACROENCAPSULATION DEVICES AND RELATED METHODSFiled as VERTEX PHARMACEUTICALS INCORPORATED2026-03-17KYLE ADAM MOTA | pending |
| CELL HOUSING DEVICEA61F 2/022, A61J 3/07, A61M 31/002, B01D2325/0283, A61J 3/074, A61K 9/0024, A61K 35/39, A61M2205/04, A61M2207/00, B01D 69/02, C12N 5/0676Filed as Vertex Pharmaceuticals Incorporated2026-01-12Christopher Thanos | pending |
| UREA-CONTAINING AGONISTS OF OREXIN RECEPTOR TYPE 2Filed as Vertex Pharmaceuticals Incorporated2026-01-02Matthew VOLGRAF | pending |
| UREA-CONTAINING AGONISTS OF OREXIN RECEPTOR TYPE 2Filed as Vertex Pharmaceuticals Incorporated2026-01-02Todd J.A. EWING | pending |
| COMPOSITIONS AND METHODS FOR STEM CELL GROWTHFiled as VERTEX PHARMACEUTICALS INCORPORATED2025-12-19AARON HOSIOS | pending |
| CELL THERAPY FOR DIABETES IN TRANSPLANT RECIPIENTSA61P 3/10, A61K 35/39, A61P 37/06, A61K 9/0019, A61K 31/00, A61K 31/365, A61K 31/436, A61K 31/5377, A61K 38/13, A61K 38/1793, A61K 38/28, A61K 39/3955, A61K2039/505, A61K2039/54, A61K2039/545, C07K 16/2866, C07K2317/76, C12N 5/00, C12N 5/0676, C12N2501/999, A61K2300/00Filed as Vertex Pharmaceuticals Incorporated2025-12-08Felicia J. Pagliuca | pending |
| CELL THERAPY FOR DIABETES IN TRANSPLANT RECIPIENTSFiled as VERTEX PHARMACEUTICALS INCORPORATED2025-12-08FELICIA J . PAGLIUCA | pending |
| MULTICOMPARTMENT MACROENCAPSULATION DEVICESA61F 2/022, A61J 3/07, A61M 31/002, B01D2325/0283, A61J 3/074, A61K 9/0024, A61K 35/39, A61M2205/04, A61M2207/00, B01D 69/02, C12N 5/0676Filed as Vertex Pharmaceuticals Incorporated2025-12-03Christopher Thanos | pending |
| Methods for Directing Lipid Nanoparticles in VivoA61K 9/127, C12N 15/1138, A61K 47/549, A61K 31/7008, A61K 31/713, C12N2310/14, C12N2310/315, C12N2310/321, C12N2310/351, C12N2310/3515, C12N2310/3521Filed as Vertex Pharmaceuticals Incorporated2025-11-25Gregoriy Aleksandrovich Dokshin | pending |
| COMPACT PROTEINSC12N 9/226, C12N2310/20, C12N 9/1007, C12N 9/78, C12N 15/102, C12N 15/113, C12N 15/52, C12N 15/625, C12N 15/8645, C12N2750/14143, C12N2830/34, C12Y 305/04Filed as VERTEX PHARMACEUTICALS INCORPORATED2025-11-10Gregoriy A. DOKSHIN | pending |
| IMPLANTATION AND TRANSPORT SYSTEMS FOR USE WITH MACROENCAPSULATION DEVICES AND RELATED METHODSA61F 2/022, A61B 50/00, A61B 50/20, A61B 50/30, A61B 17/3468, A61F 2/0095, A61F2250/006, A61M 37/0069, C12M 25/16Filed as Vertex Pharmaceuticals Incorporated2025-10-10Adam MacMillan | pending |
| IMPLANTATION AND TRANSPORT SYSTEMS FOR USE WITH MACROENCAPSULATION DEVICES AND RELATED METHODSFiled as VERTEX PHARMACEUTICALS INCORPORATED2025-10-10ADAM MACMILLAN | pending |
| ENHANCED DIFFERENTIATION OF PANCREATIC ISLET CELLSC12N 5/0676, A61K 35/39, C12N 5/0678, C12N2500/32, C12N2501/115, C12N2501/117, C12N2501/16, C12N2501/385, C12N2501/41, C12N2501/727, C12N2506/02, C12N2506/45Filed as Vertex Pharmaceuticals Incorporated2025-10-01Chunhui Xie | pending |
| ENHANCED DIFFERENTIATION OF PANCREATIC ISLET CELLSC12N 5/0676, A61K 35/39, C12N 5/0678, C12N2500/32, C12N2501/115, C12N2501/117, C12N2501/16, C12N2501/385, C12N2501/41, C12N2501/727, C12N2506/02, C12N2506/45Filed as Vertex Pharmaceuticals Incorporated2025-10-01Chunhui Xie | pending |
| MACROCYCLIC SULFONAMIDE MODULATORSC07D 498/08, C07D 498/20, A61P 25/00, A61K 31/407, A61K 31/439, C07D 498/10, C07D 498/18Filed as Vertex Pharmaceuticals Incorporated2025-09-17Jun Myun AHN | pending |
| MACROCYCLIC SULFONAMIDE MODULATORSFiled as VERTEX PHARMACEUTICALS INCORPORATED2025-09-17JUN MYUN AHN | pending |
| Materials and Methods for Treatment of Pain Related DisordersC07K 14/705, C12N 15/86, C12N 15/907, C12N2310/20, A61P 43/00, A61P 25/02, A61P 25/04, A61P 25/00, A61P 29/00, A61K 35/30, A61K 38/465, A61K 48/0008, A61K 48/005, C07K 14/47, C12N 9/22, C12N 15/11, C12N 15/113, C12N 15/1138, C12N2750/14143, C12N2800/80Filed as Vertex Pharmaceuticals Incorporated2025-09-16Ante Sven Lundberg | pending |
| COMPOSITIONS AND METHODS FOR STEM CELL GROWTHFiled as Vertex Pharmaceuticals Incorporated2025-08-29Aaron Hosios | pending |
| PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATORC07D 401/14, A61P 43/00, A61K 31/4439, C07D 231/20, C07D 401/04, C07D 405/04Filed as Vertex Pharmaceuticals Incorporated2025-08-20Paul T. Angell | pending |
| ENHANCED DIFFERENTIATION OF BETA CELLSA61K 38/28, C12N 5/0676, A61K 31/192, A61K 31/201, A61K 31/375, A61K 31/437, A61K 31/4525, A61K 31/454, A61K 31/506, A61K 31/519, A61K 33/30, A61K 35/37, A61K 35/39, A61K 38/385, A61K 45/06, C12N2500/22, C12N2500/33, C12N2500/36, C12N2500/38, C12N2501/15, C12N2501/155, C12N2501/72, C12N2501/727, C12N2501/73, C12N2506/03, A61K2300/00Filed as Vertex Pharmaceuticals Incorporated2025-08-14Bryce Carey | pending |
| MACROENCAPSULATION DEVICES INCLUDING IMMUNOMODULATORY COMPOUNDSFiled as Vertex Pharmaceuticals Incorporated2025-08-13Christopher Thanos | pending |
| BIARYL AMIDE-CONTAINING AGONISTS OF OREXIN RECEPTOR TYPE 2Filed as VERTEX PHARMACEUTICALS INCORPORATED2025-07-31Matthew VOLGRAF | pending |
| DOSAGE FORMS AND DOSING REGIMENS FOR TREATING PAINFiled as VERTEX PHARMACEUTICALS INCORPORATED2025-07-31SIYING LIU | pending |
| CELL THERAPY FOR DIABETES IN TRANSPLANT RECIPIENTSFiled as Vertex Pharmaceuticals Incorporated2025-06-30Felicia J. Pagliuca | pending |
| HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAINC07D 471/04, A61P 25/02, A61P 25/04, A61K 31/4375, A61K 31/444, C07D 519/00Filed as Vertex Pharmaceuticals Incorporated2025-06-27Elizabeth BECK | pending |
| IMPLANTATION DEVICES, SYSTEM, AND METHODSA61M 37/0069, A61M 31/002, A61M2202/09, A61M2205/586, A61K 35/00, A61M 5/14276, A61M 37/00Filed as Vertex Pharmaceuticals Incorporated2025-06-27Christopher Thanos | pending |
| METHODS OF TREATMENT FOR CYSTIC FIBROSISFiled as VERTEX PHARMACEUTICALS INCORPORATED2025-06-27FREDRICK VAN GOOR | pending |
| HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAINFiled as VERTEX PHARMACEUTICALS INCORPORATED2025-06-27ELIZABETH BECK | pending |
| PRODUCTION OF PANCREATIC BETA CELLS IN PERFUSION CULTURESFiled as VERTEX PHARMACEUTICALS INCORPORATED2025-06-23STEPHANIE JINYI DOONG | pending |
| RE-AGGREGATION OF STEM CELL-DERIVED PANCREATIC BETA CELLSA61K 9/5036, C12N 5/0676, A61K 9/0019, A61K 35/39, C12N 5/0031, C12N 5/0671, C12N2506/22, C12N2509/10, C12N2527/00Filed as Vertex Pharmaceuticals Incorporated2025-06-06Yeh-Chuin POH | pending |
| PROCESS FOR THE SYNTHESIS OF SUBSTITUTED TETRAHYDROFURAN MODULATORS OF SODIUM CHANNELSA61P 29/00, C07D 405/02, C07D 405/12, A61K 9/2013, A61K 9/2054, A61K 31/443, C07B2200/13, C07D 213/61, C07D 213/78, C07D 213/79, C07D 307/12, C07D 307/20, C07D 307/24, C07D 307/32, C07D 307/68, C07D 401/06, C07D 405/04, C07D 405/14, C07D 471/08Filed as VERTEX PHARMACEUTICALS INCORPORATED2025-06-05Cristian HARRISON | pending |
| NOVEL MEDIA CONDITIONS AND METHODS OF USEFiled as VERTEX PHARMACEUTICALS INCORPORATED2025-06-04TIEBIN WANG | pending |
| METHODS OF TREATMENT FOR CYSTIC FIBROSISA61K 31/4439, A61P 11/00, A61K 31/404, A61K 31/443, A61K 31/47, A61K2300/00Filed as Vertex Pharmaceuticals Incorporated2025-05-29Weichao George Chen | pending |
| SUBSTITUTED MACROCYCLIC AMINE MODULATORS OF OREXIN RECEPTOR 2A61K 31/501, C07D 498/04, A61P 25/00, A61K 31/439, A61K 31/444, A61K 31/497, C07D 498/08Filed as Vertex Pharmaceuticals Incorporated2025-05-22Matthew Volgraf | pending |
| MODULATOR OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATORA61K 31/455, C07D 401/14, A61P 11/00, A61K 31/4439, A61K 31/519, A61K 31/5365, C07B2200/05, C07B2200/13, C07D 231/20, C07D 401/04, C07D 471/14, C07D 498/14Filed as Vertex Pharmaceuticals Incorporated2025-05-13Alexander Russell Abela | pending |
| NOVEL ISLET POTENCY ASSAYFiled as VERTEX PHARMACEUTICALS INCORPORATED2025-05-05NAYARA LEITE | pending |
| DIFFERENTIATION OF PANCREATIC ISLET CELLSFiled as VERTEX PHARMACEUTICALS INCORPORATED2025-05-05NAYARA LEITE | pending |
| MODIFIED UROKINASE-TYPE PLASMINOGEN ACTIVATOR POLYPEPTIDES AND METHODS OF USEC12N 9/6462, A61P 27/02, A61P 9/10, A61P 29/00, A61K 31/727, A61K 38/00, A61K 38/49, A61K 45/06, A61K2300/00, C07K 14/765, C07K2319/00, C07K2319/01, C07K2319/02, C07K2319/20, C07K2319/30, C07K2319/31, C07K2319/50, C07K2319/70, C12N 15/52, C12N 15/62, C12Y 304/21031, C12Y 304/21073Filed as Vertex Pharmaceuticals Incorporated2025-05-02Edwin L. Madison | pending |
| GENETICALLY ENGINEERED CELLSA61K 35/28, A61K 35/545, C12N 5/0606, C12N2310/20, C12N 9/226, C07K 14/47, C07K 14/705, C07K 14/70596, C12N 15/11, C12N 15/907, C12N2510/00Filed as Vertex Pharmaceuticals Incorporated2025-05-01Michael Cooke | pending |
| GENETICALLY ENGINEERED CELLSFiled as VERTEX PHARMACEUTICALS INCORPORATED2025-04-29MICHAEL COOKE | pending |
| CRYSTALLINE FORMS OF CFTR MODULATORSC07D 471/08, C07D 513/22, A61P 43/00, A61P 11/00, A61K 31/435, C07B2200/13Filed as Vertex Pharmaceuticals Incorporated2025-04-22Yi Shi | pending |
| ISLET CELL MANUFACTURING COMPOSITIONS AND METHODS OF USEA61K 35/39, C07D 401/14, C12N 5/0676, C12N 5/0678, A61P 5/50, A61P 3/10, A61K 9/0014, A61K 9/0019, A61K 9/0053, A61L 27/3804, A61L 27/3834, A61L 27/3895, A61L 27/50, A61L 27/54, A61L2300/30, A61L2300/414, A61L2300/434, A61L2300/436, A61L2300/62, C07D 401/04, C07K 14/495, C07K 14/50, C07K 14/62, C12N2501/117, C12N2501/15, C12N2501/155, C12N2501/16, C12N2501/385, C12N2501/41, C12N2501/999, C12N2506/02, C12N2506/23Filed as Vertex Pharmaceuticals Incorporated2025-04-18Austin Thiel | pending |
| Materials and Methods for Treatment of HemoglobinopathiesA61K 38/465, A61K 48/0066, C12N 5/0647, C12N 15/102, C12N2310/20, A61P 7/06, A61P 7/00, A61K 31/395, A61K 35/28, A61K 48/0008, A61K 48/0058, A61K 48/0075, C12N 9/22, C12N 15/113, C12N2310/315, C12N2506/11, C12N2506/1346, C12N2506/45, C12N2510/00Filed as Vertex Pharmaceuticals Incorporated2025-04-18Chad Albert Cowan | pending |
| ANTI-CD74 ANTIBODY COMPOSITIONS AND METHODSFiled as Vertex Pharmaceuticals Incorporated2025-04-11Caitlin Stein | pending |
| METHODS OF TREATMENT OF MYOTONIC DYSTROPHY TYPE 1Filed as VERTEX PHARMACEUTICALS INCORPORATED2025-03-26Pei LI | pending |
| MUCIN-5B (MUC5B) TARGETED SIRNA AND ANTISENSE OLIGONUCLEOTIDES AND METHODS OF USE THEREOFC12N 15/113, A61P 11/00, C12N2310/11, C12N2310/14, C12N2310/315, C12N2310/321, C12N2310/322, C12N2310/332, C12N2310/346, C12N2310/3515, C12N2310/3521, C12N2320/32, C12N2310/3533Filed as Vertex Pharmaceuticals Incorporated2025-03-19Diego D'Astolfo | pending |
| MUCIN-5B (MUC5B) TARGETED SIRNA AND ANTISENSE OLIGONUCLEOTIDES AND METHODS OF USE THEREOFFiled as VERTEX PHARMACEUTICALS INCORPORATED2025-03-19DIEGO D'ASTOLFO | pending |
| PHARMACEUTICAL COMPOSITIONS OF ALPHA-1 ANTITRYPSIN MODULATORSFiled as VERTEX PHARMACEUTICALS INCORPORATED2025-03-12KATHLEEN PAIGE SOKOLOWSKY | pending |
| ENHANCED DIFFERENTIATION OF PANCREATIC ISLET CELLSC12N 5/0676, A61K 35/39, C12N 5/0678, C12N2500/32, C12N2501/115, C12N2501/117, C12N2501/16, C12N2501/385, C12N2501/41, C12N2501/727, C12N2506/02, C12N2506/45Filed as Vertex Pharmaceuticals Incorporated2025-03-05Chunhui Xie | pending |
| EXCISION OF EXON 53 FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHYFiled as VERTEX PHARMACEUTICALS INCORPORATED2025-02-26YANG GUO | pending |
| N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELSA61P 29/00, C07D 405/12, A61K 31/443Filed as VERTEX PHARMACEUTICALS INCORPORATED2025-02-20Elizabeth Mary Beck | pending |
| MACROCYCLIC SULFONAMIDE MODULATORSFiled as Vertex Pharmaceuticals Incorporated2025-02-12Ming CHEN | pending |
| COMPOSITIONS FOR THE TREATMENT OF CFTR-MEDIATED DISEASESA61K 9/1652, A61K 31/439, A61P 11/00, A61K 9/1611, A61K 9/1617, A61K 9/1623, A61K 31/404, A61K 31/444, A61K 31/47Filed as Vertex Pharmaceuticals Incorporated2025-02-06Radhika KARKARE | pending |
| COMPOSITIONS FOR THE TREATMENT OF CFTR-MEDIATED DISEASESFiled as VERTEX PHARMACEUTICALS INCORPORATED2025-02-06RADHIKA KARKARE | pending |
Filings are matched to the company by applicant name, so a subsidiary filing under its own name is only here if that name resolves to this company. The applicant is printed as filed, which makes a wrong match visible. A patent is not a product: most applications are never granted, and most grants are never built.
More on VRTX
Company overviewEverything on VRTX in one place, with the price.SEC filingsWhat VRTX's 8-Ks say happened: results, departures, auditor changes.Insider tradingWhat VRTX's own officers and directors buy and sell.Who owns itEvery manager reporting a position in VRTX.Funds holding itWhich funds and ETFs hold VRTX, and how big a bet.LobbyingWhat VRTX spends lobbying Congress, and on what.Who lobbies for itThe lobbyists on VRTX's account, and who they worked for.